<DOC>
	<DOCNO>NCT02214225</DOCNO>
	<brief_summary>This study ass immune ( antibody ) response safety bioCSL split virion , inactivated quadrivalent influenza vaccine , comparison US license 2014/2015 trivalent influenza vaccine ( bioCSL TIV-1 ) , trivalent influenza vaccine contain alternate B strain ( bioCSL TIV-2 ) , healthy adult volunteer age 18 year .</brief_summary>
	<brief_title>A Study Evaluate Immunogenicity Safety bioCSL Quadrivalent Influenza Vaccine ( QIV ) Adults Aged 18 Years Above .</brief_title>
	<detailed_description>This multicenter , randomize , double-blinded study conduct 2014-2015 Northern Hemisphere influenza immunization season evaluate non-inferior immune response bioCSL QIV bioCSL TIV-1 bioCSL TIV-2 along safety healthy male female adult age ≥ 18 year . Each vaccinate subject maximum 25 day on-study period six month safety follow-up .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males nonpregnant female age ≥ 18 year time vaccination . Females childbearing potential ( i.e. , ovulate , premenopausal , surgically sterile ) must abstinent willing use medically accept contraceptive regimen duration Onstudy period . Females childbearing potential must return negative urine pregnancy test result prior vaccination vaccine . Known hypersensitivity previous dose influenza vaccine allergy egg , chicken protein , neomycin , polymyxin , component bioCSL influenza vaccine . Vaccination influenza previous 6 month . Known history GuillainBarré Syndrome demyelinate disease . Clinical sign active infection and/or oral temperature ≥ 100.4°F ( 38.0°C ) . A clinically significant medical condition . Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>